Table 5.

Reported side effects during MTX treatment

Adverse event, n (%)	All patients (n = 60)	MTX responders (n = 49)	MTX non-responders (n = 11)	P value
Adverse event occurred	19 (31.7)	15 (30.6)	4 (36.4)	0.990
Gastrointestinal-related	11 (18.3)	9 (18.4)	2 (18.2)	1.000
Nausea, n (%)	6 (10.0)	5 (10.2)	1 (9.1)	1.000
Epigastric discomfort, n (%)	2 (3.3)	2 (4.1)	0	1.000
Anorexia, n (%)	3 (5.0)	2 (4.1)	1 (9.1)	0.462
Abdominal distension, n (%)	4 (6.7)	4 (8.2)	0	1.000
Gingivitis, n (%)	1 (1.7)	1 (2.0)	0	1.000
Infection, n (%)	5 (8.3)	4 (8.2)	1 (9.1)	0.395
Pulmonary	3 (5.0)	3 (6.1)	0
The upper respiratory tract	1 (1.7)	0	1 (9.1)
Oral cavity	1 (1.7)	1 (2.0)	0
Headache/uneasy, n (%)	6 (10.0)	5 (10.2)	1 (9.1)	1.000
Fatigue, n (%)	3 (5.0)	1 (2.0)	2 (18.2)	0.084
Hepatic function or WBC declined, n (%)	4 (6.7)	4 (8.2)	0	1.000
Aminotransferase elevations, n (%)	3 (5.0)	3 (6.1)	0	1.000
WBC level declined, n (%)	1 (1.7)	1 (2.0)	0	1.000
Drug discontinuation due to AEs, n (%)	4 (6.7)	3 (6.1)	1 (9.1)	0.566

AEs: adverse events.